Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus cabozantinib in advanced sarcomas
2020-002366-13Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and cabozantinib in Malignant Fibrous Histiocytoma (MFH), osteosarcoma (OS), Ewing sarcoma and 1 more (3 cohorts), sponsored by Institut Bergonié. Primary endpoints: 6-month non-progression (RECIST v1.1) in undifferentiated pleomorphic sarcoma, 6-month non-progression (RECIST v1.1) in osteosarcoma and 1 more. Started Oct 2021; status: active.
02
Drugs
pembrolizumabcabozantinib
03
Conditions
Malignant Fibrous Histiocytoma (MFH)osteosarcoma (OS)Ewing sarcomaBone and soft tissue sarcoma
Beyond the preview
Go deeper on 2020-002366-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002366-13.